Abstract
Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have